ResearcherZhejiang Chinese Medical UniversityActive in the last 2 years

Ran Ni

Provisional: name at one institution (moderate confidence, 0.60), identity_conf@1As of 7 November 2026

Known by name at one institution; no external author ID yet. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2023: 1 paper · 2024: 1 paper

Papers 2

Advances of immune-checkpoint inhibition of CTLA-4 in pancreatic cancer. Co-author DOI 10.1016/j.biopha.2024.117430 ↗
An Update on Gemcitabine-Based Chemosensitization Strategies in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.31083/j.fbl2812361 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Ran Tao · 2 shared papers, 2023–2024 · strength 0.58
- Paper Advances of immune-checkpoint inhibition of CTLA-4 in pancreatic cancer. DOI 10.1016/j.biopha.2024.117430 ↗
- Paper An Update on Gemcitabine-Based Chemosensitization Strategies in Pancreatic Ductal Adenocarcinoma. DOI 10.31083/j.fbl2812361 ↗
Zongting Gu · 1 shared paper, 2023 · strength 0.22
- Paper An Update on Gemcitabine-Based Chemosensitization Strategies in Pancreatic Ductal Adenocarcinoma. DOI 10.31083/j.fbl2812361 ↗
Tianpeng Zhang · 1 shared paper, 2023 · strength 0.22
- Paper An Update on Gemcitabine-Based Chemosensitization Strategies in Pancreatic Ductal Adenocarcinoma. DOI 10.31083/j.fbl2812361 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.